These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32989933)

  • 1. Letter to the Editor: The Interpretation of COVID-19 Seroprevalence Study Should Be Cautious.
    Lee J; Kim SY; Sung H; Choe YJ; Hong KH
    J Korean Med Sci; 2020 Sep; 35(38):e338. PubMed ID: 32989933
    [No Abstract]   [Full Text] [Related]  

  • 2. The Author's Response: COVID-19 Antibody Test at Population Level: Why Timing Is the Key.
    Song SK; Lee DH; Cho MR
    J Korean Med Sci; 2020 Sep; 35(38):e339. PubMed ID: 32989934
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter to the editor: COVID-19: how accurate are seroprevalence studies?
    Kadkhoda K
    Euro Surveill; 2020 Jul; 25(30):. PubMed ID: 32734860
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR.
    Kim JY
    J Korean Med Sci; 2020 Feb; 35(7):e88. PubMed ID: 32080992
    [No Abstract]   [Full Text] [Related]  

  • 5. IgG Seroprevalence of COVID-19 among Individuals without a History of the Coronavirus Disease Infection in Daegu, Korea.
    Song SK; Lee DH; Nam JH; Kim KT; Do JS; Kang DW; Kim SG; Cho MR
    J Korean Med Sci; 2020 Jul; 35(29):e269. PubMed ID: 32715672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter to Editor: Strategy for Hospitalization and Discharge of COVID-19 Patients: Based on the Nationwide Clinical Course Analysis.
    Kim Y; Sung HK; Bang JH; Koh IS; Joh JS; Ju YS; Min HS; Chin BS; Chung KH
    J Korean Med Sci; 2020 Sep; 35(38):e353. PubMed ID: 32989937
    [No Abstract]   [Full Text] [Related]  

  • 7. Authors' response: COVID-19: how accurate are seroprevalence studies?
    Cassaniti I; Percivalle E; Sarasini A; Cambiè G; Batisti Biffignandi G; Cereda D; Baldanti F
    Euro Surveill; 2020 Jul; 25(30):. PubMed ID: 32734854
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter to the Editor: Risk Communication, Shared Responsibility, and Mutual Trust Are Matters: Real Lessons from Closure of Eunpyeong St. Mary's Hospital Due to Coronavirus Disease 2019 in Korea.
    Kim T; Lee JY
    J Korean Med Sci; 2020 Apr; 35(16):e159. PubMed ID: 32329262
    [No Abstract]   [Full Text] [Related]  

  • 9. SARS-CoV-2 seroprevalence in COVID-19 hotspots.
    Eckerle I; Meyer B
    Lancet; 2020 Aug; 396(10250):514-515. PubMed ID: 32645348
    [No Abstract]   [Full Text] [Related]  

  • 10. Assessing the extent of SARS-CoV-2 circulation through serological studies.
    Koopmans M; Haagmans B
    Nat Med; 2020 Aug; 26(8):1171-1172. PubMed ID: 32719488
    [No Abstract]   [Full Text] [Related]  

  • 11. Seroprevalence of SARS-Cov-2 in 646 professionals at the Rothschild Foundation Hospital (ProSeCoV study).
    Mesnil M; Joubel K; Yavchitz A; Miklaszewski N; Devys JM
    Anaesth Crit Care Pain Med; 2020 Oct; 39(5):595-596. PubMed ID: 32861816
    [No Abstract]   [Full Text] [Related]  

  • 12. Are we underestimating seroprevalence of SARS-CoV-2?
    Burgess S; Ponsford MJ; Gill D
    BMJ; 2020 Sep; 370():m3364. PubMed ID: 32883673
    [No Abstract]   [Full Text] [Related]  

  • 13. SARS-CoV-2 seroprevalence in Spain.
    George TP
    Lancet; 2020 Nov; 396(10261):1484. PubMed ID: 33160560
    [No Abstract]   [Full Text] [Related]  

  • 14. SARS-CoV-2 seroprevalence in Spain.
    Hoffmann C; Wolf E
    Lancet; 2020 Nov; 396(10261):1484. PubMed ID: 33160562
    [No Abstract]   [Full Text] [Related]  

  • 15. Seroprevalence and presentation of SARS-CoV-2 in pregnancy.
    Crovetto F; Crispi F; Llurba E; Figueras F; Gómez-Roig MD; Gratacós E
    Lancet; 2020 Aug; 396(10250):530-531. PubMed ID: 32771084
    [No Abstract]   [Full Text] [Related]  

  • 16. SARS-CoV-2 seroprevalence in Spain - Authors' reply.
    Pollán M; Pérez-Gómez B; Pastor-Barriuso R; Oteo J; Pérez-Olmeda M; Yotti R;
    Lancet; 2020 Nov; 396(10261):1484-1485. PubMed ID: 33160561
    [No Abstract]   [Full Text] [Related]  

  • 17. SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020.
    Fischer B; Knabbe C; Vollmer T
    Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020.
    Sood N; Simon P; Ebner P; Eichner D; Reynolds J; Bendavid E; Bhattacharya J
    JAMA; 2020 Jun; 323(23):2425-2427. PubMed ID: 32421144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroprevalence of SARS-CoV-2 antibodies among pregnant women in Estonia: A call for epidemiological studies.
    Veerus P; Salumets A; Naaber P; Krjutškov K; Tilk K; Laanpere M; Uusküla A
    Acta Obstet Gynecol Scand; 2020 Dec; 99(12):1736-1737. PubMed ID: 32970836
    [No Abstract]   [Full Text] [Related]  

  • 20. In Reply to the Letter to the Editor Regarding "Neurological Impact of Coronavirus Disease (COVID-19): Practical Considerations for the Neuroscience Community".
    Scullen T; Mathkour M; Keen JR
    World Neurosurg; 2020 Oct; 142():535-536. PubMed ID: 32585382
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.